The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the approval of Wegovy tablets, containing the active ingredient semaglutide, as a treatment option for adults who are obese or overweight with at least one weight-related health condition. This approval makes the UK the third country to authorise these oral GLP-1 receptor agonist tablets, following the United States and the United Arab Emirates.

Previously, patients in the UK could only access Wegovy as an injectable medication. The introduction of an oral tablet form is expected to improve patient access and convenience, particularly for those who may find injections less suitable.

Regulatory and Clinical Context

Wegovy tablets are approved for adults with a body mass index (BMI) of 30 or above, or those with a BMI between 27 and 30 who have at least one weight-related health condition. Clinical trials have reported that patients on the highest doses of semaglutide achieved an average weight reduction of approximately 14-17% over 64 weeks.

Despite MHRA approval, Wegovy tablets are not yet recommended for NHS prescription pending guidance from the National Institute for Health and Care Excellence (NICE). Until NICE approval is granted, patients must obtain the medication via private prescription, with prices yet to be confirmed.

Usage and Considerations

  • Wegovy tablets require administration on an empty stomach after fasting for at least eight hours, followed by avoidance of food or drink for 30 minutes.
  • Common side effects include gastrointestinal symptoms such as nausea, diarrhoea, constipation, and vomiting.
  • Patients experiencing adverse effects are advised to consult healthcare professionals and report side effects through the MHRA’s Yellow Card scheme.

Expert Perspectives

Healthcare professionals emphasise that while oral weight-loss medication may enhance accessibility and ease of use, it is not a standalone solution. Weight-loss drugs should be integrated into broader strategies involving nutrition, physical activity, and behavioural support.

Experts also highlight the need for continued public health efforts addressing the wider environment influencing obesity, including food systems and lifestyle factors.

Research-Use Disclaimer

This article is intended for educational purposes and reflects current regulatory and clinical information. It does not provide medical advice or treatment recommendations. Readers interested in peptide research and product literacy can explore relevant resources at https://sveltalabs.com.